Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Apr 29, 2023 10:42pm
160 Views
Post# 35421311

RE:RE:RE:RE:RE:ASCO relevance

RE:RE:RE:RE:RE:ASCO relevance
UPON APPROVAL Noteable , upon approval so how many times to I have to keep repeating this for you to understand. We do not have approval and therefore need to get the phase 3 trials underway in a timely manner and hopefully with a relatively smaller patient population which is possible with the biomarkers to help with all of this.
You do not always have to be so contentious all the time. It is just a free flow of information and concerns that are still justifiable and my simple point was that I would prefer a buyout over a partnership to remove all doubt for all of the shareholders. Pretty simple concept.
I of course am hoping for any deal after all of these years and we still do have AN in the background which appeears to be waiting on ASCO and I am sure that their sites will most likely already be in place.
We will know when we know and that will only be when an announcement is made.
<< Previous
Bullboard Posts
Next >>